888-500-0370 mbcn@mbcn.org

advvocacy

FDA Approves Kisqali for Breast Cancer

Kisqali (ribociclib), a CDK 4/6 inhibitor, gained approval from the Food and Drug Administration (FDA) for the frontline treatment of postmenopausal women with hormone-receptor (HR)–positive, HER2-negative advanced breast cancer. Read  more